BioMarin’s $4.8 Billion Buyout Bombshell: Amicus Therapeutics (FOLD) Stock Soars on 33% Premium Offer

BioMarin just dropped a $4.8 billion check on the table for Amicus Therapeutics. The offer carries a hefty 33% premium, instantly making FOLD stock the hottest ticket in biotech.

The Deal That Shook the Street

This isn't a friendly merger chat—it's a full-scale acquisition play. BioMarin's move signals a massive bet on Amicus's pipeline, valuing the company at a level that turns heads and raises eyebrows in equal measure. The premium suggests BioMarin sees something the broader market might have missed, or is desperately trying to buy its way into a new growth story.

Why This Number Matters

A 33% premium isn't just a nice bump; it's a statement. In an era where funding can be fickle, a cash offer of this magnitude cuts through the noise. It bypasses the usual shareholder drama and puts a definitive price on potential. For Amicus shareholders, it's a sudden windfall. For BioMarin, it's a costly shortcut to innovation—the kind of move that either defines a legacy or becomes a case study in overpaying.

The market's initial roar of approval will soon meet the cold, hard scrutiny of integration. Can BioMarin extract enough value to justify that premium? Or is this just another expensive roll of the dice in the biotech casino, where the house always wins in the long run? Time will tell, but for now, the deal is done, and the numbers are speaking for themselves.

TLDR

• BioMarin Pharmaceuticals agreed to acquire Amicus Therapeutics for $4.8 billion in an all-cash deal at $14.50 per share
• The acquisition price represents a 33% premium to Amicus’ closing price on December 18
• TD Cowen downgraded Amicus stock from Buy to Hold and cut the price target from $20 to $14.50 following the buyout announcement
• The deal adds two lysosomal storage disorder treatments to BioMarin’s portfolio, including Galafold for Fabry disease and a Pompe disease treatment
• Amicus reported Q3 2025 earnings that beat expectations with EPS of $0.06 versus forecasted $0.03 and revenue of $169.1 million against projected $165.4 million

BioMarin Pharmaceuticals agreed to acquire Amicus Therapeutics for approximately $4.8 billion in cash. The deal values Amicus at $14.50 per share.

Amicus Therapeutics, Inc., FOLD

The acquisition announcement came on December 19. The offer price represents a 33% premium to Amicus’ closing price on December 18.

Following the announcement, TD Cowen downgraded Amicus stock from Buy to Hold. The firm also lowered its price target to $14.50 from $20.00.

BioMarin Pharmaceutical Inc. agreed to buy Amicus Therapeutics Inc. for about $4.8 billion to expand its portfolio of treatments for rare diseases. https://t.co/ChUMv6l4pJ

— Bloomberg (@business) December 19, 2025

The stock currently trades at $14.18, NEAR its 52-week high of $14.36. Technical indicators show the stock in overbought territory.

The deal expands BioMarin’s presence in the rare disease market. Amicus brings two treatments targeting lysosomal storage disorders to the table.

Strategic Fit for BioMarin

TD Cowen called BioMarin a “logical acquirer” for Amicus. Both companies’ flagship treatments align with BioMarin’s rare enzyme replacement therapy business.

Galafold, Amicus’ oral medication for Fabry disease, forms a key part of the acquisition. BioMarin also secured intellectual property settlements with Aurobindo and Lupin.

These settlements protect Galafold’s intellectual property until 2037. The agreements provide long-term certainty for the treatment’s market exclusivity.

The deal also includes Amicus’ Pompe disease treatment called PomOp. BioMarin will gain U.S. rights to DMX-200, an investigational drug in Phase 3 trials for a rare kidney disease.

Recent Financial Performance

Amicus reported strong third-quarter 2025 results before the buyout announcement. The company posted earnings per share of $0.06, beating the $0.03 forecast.

Revenue came in at $169.1 million, surpassing the expected $165.4 million. The company operates with gross profit margins near 90%.

Analysts expect Amicus to become profitable this year. The strong financial performance was driven by robust sales of key products.

Strategic market expansion also contributed to the revenue growth. Amicus represented 2.7% of The Biotech Growth Trust PLC’s net asset value at the time of the announcement.

BioMarin expects the deal to boost revenue growth. The acquisition is projected to be accretive to non-GAAP diluted earnings per share within the first year after closing.

The companies expect to close the transaction in the second quarter of 2026. Neither company disclosed specific regulatory approvals required for completion.